These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 26602217)

  • 1. End Points Must Be Clinically Meaningful for Drug Development in Nonalcoholic Fatty Liver Disease.
    Sanyal AJ; Neuschwander-Tetri BA; Tonascia J
    Gastroenterology; 2016 Jan; 150(1):11-3. PubMed ID: 26602217
    [No Abstract]   [Full Text] [Related]  

  • 2. Time to Replace Assessment of Liver Histology With MR-Based Imaging Tests to Assess Efficacy of Interventions for Nonalcoholic Fatty Liver Disease.
    Byrne CD; Targher G
    Gastroenterology; 2016 Jan; 150(1):7-10. PubMed ID: 26602219
    [No Abstract]   [Full Text] [Related]  

  • 3. Regulatory Science and Drug Approval for Alcoholic and Nonalcoholic Steatohepatitis.
    Sanyal AJ; Miller V
    Gastroenterology; 2016 Jun; 150(8):1723-7. PubMed ID: 26924092
    [No Abstract]   [Full Text] [Related]  

  • 4. A non-invasive prediction model for non-alcoholic steatohepatitis in paediatric patients with non-alcoholic fatty liver disease.
    Eng K; Lopez R; Liccardo D; Nobili V; Alkhouri N
    Dig Liver Dis; 2014 Nov; 46(11):1008-13. PubMed ID: 25106814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease.
    Safadi R; Konikoff FM; Mahamid M; Zelber-Sagi S; Halpern M; Gilat T; Oren R;
    Clin Gastroenterol Hepatol; 2014 Dec; 12(12):2085-91.e1. PubMed ID: 24815326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Astaxanthin Improves Nonalcoholic Fatty Liver Disease in Werner Syndrome with Diabetes Mellitus.
    Takemoto M; Yamaga M; Furuichi Y; Yokote K
    J Am Geriatr Soc; 2015 Jun; 63(6):1271-3. PubMed ID: 26096415
    [No Abstract]   [Full Text] [Related]  

  • 7. Factors to Consider in Development of Drugs for Pediatric Nonalcoholic Fatty Liver Disease.
    Vos MB; Dimick-Santos L; Mehta R; Omokaro SO; Taminiau J; Schabel E; Kleiner DE; Szitanyi P; Socha P; Schwimmer JB; Noviello S; Silberg DG; Torstenson R; Miller V; Lavine JE;
    Gastroenterology; 2019 Dec; 157(6):1448-1456.e1. PubMed ID: 31520612
    [No Abstract]   [Full Text] [Related]  

  • 8. NONALCOHOLIC FATTY LIVER DISEASE AND ITS COMPLICATIONS--ASSESSING THE POPULATION AT RISK. A SMALL SERIES REPORT AND LITERATURE REVIEW.
    Livadariu R; Timofte D; Danilă R; Ionescu L; Diaconu C; Soroceanu P; Sângeap AM; Drug VL; Trifan A
    Rev Med Chir Soc Med Nat Iasi; 2015; 119(2):346-52. PubMed ID: 26204635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonalcoholic steatohepatitis (NASH) drugs market.
    Cassidy S; Syed BA
    Nat Rev Drug Discov; 2016 Nov; 15(11):745-746. PubMed ID: 27807356
    [No Abstract]   [Full Text] [Related]  

  • 10. An update on nonalcoholic fatty liver disease.
    Provencher DM
    JAAPA; 2014 Jul; 27(7):18-22. PubMed ID: 24901731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum proteome of nonalcoholic fatty liver disease: a multimodal approach to discovery of biomarkers of nonalcoholic steatohepatitis.
    Miller MH; Walsh SV; Atrih A; Huang JT; Ferguson MA; Dillon JF
    J Gastroenterol Hepatol; 2014 Oct; 29(10):1839-47. PubMed ID: 24750217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Variants of the course of non-alcoholic fatty liver disease in patients with ischemic heart disease and possibility of hypolipidemic therapy].
    Kurliak NV
    Wiad Lek; 2014; 67(2 Pt 2):344-7. PubMed ID: 25796866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CKD and nonalcoholic fatty liver disease.
    Targher G; Chonchol MB; Byrne CD
    Am J Kidney Dis; 2014 Oct; 64(4):638-52. PubMed ID: 25085644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of sequential proton density fat fraction for quantification of hepatic steatosis in nonalcoholic fatty liver disease.
    Idilman IS; Keskin O; Elhan AH; Idilman R; Karcaaltincaba M
    Scand J Gastroenterol; 2014 May; 49(5):617-24. PubMed ID: 24694249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pediatric nonalcoholic fatty liver disease: a comprehensive review.
    Lindbäck SM; Gabbert C; Johnson BL; Smorodinsky E; Sirlin CB; Garcia N; Pardee PE; Kistler KD; Schwimmer JB
    Adv Pediatr; 2010; 57(1):85-140. PubMed ID: 21056736
    [No Abstract]   [Full Text] [Related]  

  • 16. [Liver diseases. Non-alcoholic fatty liver disease].
    Bernal Reyes R
    Rev Gastroenterol Mex; 2010 Aug; 75 Suppl 1():181-3. PubMed ID: 20959244
    [No Abstract]   [Full Text] [Related]  

  • 17. Blood redox status is associated with the likelihood of nonalcoholic fatty liver disease irrespectively of diet's total antioxidant capacity.
    Georgoulis M; Fragopoulou E; Kontogianni MD; Margariti A; Boulamatsi O; Detopoulou P; Tiniakos D; Zafiropoulou R; Papatheodoridis G
    Nutr Res; 2015 Jan; 35(1):41-8. PubMed ID: 25530013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progress in the search for circulating biomarkers of nonalcoholic fatty liver disease.
    Amacher DE
    Biomarkers; 2014 Nov; 19(7):541-52. PubMed ID: 25189636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A need for speed: Signals in drug development.
    Nat Med; 2012 Dec; 18(12):1730-1. PubMed ID: 23223053
    [No Abstract]   [Full Text] [Related]  

  • 20. In vivo (1)H-MRS hepatic lipid profiling in nonalcoholic fatty liver disease: an animal study at 9.4 T.
    Lee Y; Jee HJ; Noh H; Kang GH; Park J; Cho J; Cho JH; Ahn S; Lee C; Kim OH; Oh BC; Kim H
    Magn Reson Med; 2013 Sep; 70(3):620-9. PubMed ID: 23023916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.